At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 204 enrolled
Drug / intervention
Tofacitinib +2 moredrug
Likely dose
Tofacitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB (CP-690,550) IN CHINESE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE CONVENTIONAL SYNTHETIC DMARD
In Brief
A Phase 3 clinical trial evaluating Tofacitinib and Placebo for Psoriatic Arthritis. Completed, enrolled 204 participants across 38 sites.
Detailed Summary
This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartAug 2018
Primary CompletionApr 2021
TodayJul 2026
First PostedApr 3, 2018
Enrollment StartAug 10, 2018
Primary CompletionApr 28, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.2 years ago
Interventions
Tofacitinibdrug
tablets, 5 mg BID x 6 months
Placeboother
tablets, to match tofacitinib 5 mg BID x 3 months
Tofacitinibdrug
tablets, 5 mg BID x 3 months